Smith & Nephew (SNNUF) Debt to Equity (2012 - 2023)

Smith & Nephew (SNNUF) reported Debt to Equity of -$0.06 for Q4 2023, up 62.35% quarter-over-quarter from -$0.15 in Q4 2021.

Smith & Nephew (SNNUF) Debt to Equity (2012 - 2023) Analysis & Trends

Smith & Nephew has reported Debt to Equity for 8 years, with the latest figure at -$0.06 in Q4 2023.

  • For the quarter ending Q4 2023, Debt to Equity changed N/A year-over-year to -$0.06; the trailing twelve-month figure through Dec 2023 stood at -$0.06 (changed N/A YoY), and the FY2023 full-year result was -$0.06, changed N/A from the prior year.
  • Debt to Equity for Q4 2023 stood at -$0.06, up from -$0.15 in the prior quarter.
  • The five-year high for Debt to Equity was -$0.06 in Q4 2023, with the low at -$0.18 in Q4 2020.
  • Historically, Debt to Equity has averaged -$0.13 across 3 years, with a median of -$0.15 in 2021.
  • The largest YoY upside for Debt to Equity was 12.52% in 2021 against a maximum downside of 12.52% in 2021.
  • Smith & Nephew's Debt to Equity stood at -$0.18 in 2020, then gained by 12.52% to -$0.15 in 2021, then soared by 62.35% to -$0.06 in 2023.
  • The last three Debt to Equity figures came in at -$0.06 (Q4 2023), -$0.15 (Q4 2021), and -$0.18 (Q4 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn 0.65
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn 0.64
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn 0.57
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn 0.06
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 0.71
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn 0.95
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn 0.27
10 Smith & Nephew - - - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -0.06
Dec 31, 2021 -0.15
Dec 31, 2020 -0.18
Dec 31, 2018 0.30
Dec 31, 2017 0.31
Dec 31, 2016 0.42
Dec 31, 2015 0.37
Sep 29, 2012 0.03
Mar 31, 2012 0.11